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Background: Breakpoint cluster region (Bcr) is a multi-domain protein that contains a C-terminal GTPase activating
protein (GAP) domain for Rac. Transglutaminase 2 (TG2) regulates Bcr by direct binding to its GAP domain. Since
TG2 has transglutaminase activity that has been implicated in the response to extreme stress, we investigated if Bcr
can also act as a substrate for TG2.
Results: We here report that activation of TG2 by calcium caused the formation of covalently cross-linked Bcr. Abr,
a protein related to Bcr but lacking its N-terminal oligomerization domain, was not cross-linked by TG2 even
though it forms a complex with it. A Bcr mutant missing the first 62 amino acid residues remained monomeric in
the presence of activated TG2, showing that this specific domain is necessary for the cross-linking reaction. Calcium
influx induced by a calcium ionophore in primary human endothelial cells caused cross-linking of endogenous Bcr,
which was inhibited by the TG2 inhibitor cystamine. Treatment of cells with cobalt chloride, a hypoxia-mimetic
that causes cellular stress, also generated high molecular weight Bcr complexes. Cross-linked Bcr protein appeared
in the TritonX-100-insoluble cell fraction and further accumulated in cells treated with a proteasome inhibitor.
Conclusions: Bcr thus represents both an interacting partner under non-stressed conditions and a target of
transglutaminase activity for TG2 during extreme stress.
Background
The breakpoint cluster region (Bcr) protein was origin-
ally identified as the amino-terminal part of a fusion
protein including the Abl tyrosine kinase, which causes
chronic myeloid leukemia and Ph-chromosome-positive
acute lymphoblastic leukemia. The fusion of Bcr to Abl
deregulates the tyrosine kinase activity of Abl [1].
Although the Bcr protein contributes a varying number
of domains to the fusion protein, the N-terminal oligo-
merization domain of Bcr is considered to be the most
critical component that allows the formation of homo-
tetramer Bcr/Abl complexes and deregulates the Abl
tyrosine kinase [2,3].
The normal (non-rearranged) BCR gene encodes a
multidomain protein. Apart from the oligomerization
domain, it additionally contains serine/threonine protein
kinase, tandem DH-PH, C2 and GTPase activating
protein (GAP) domains. The latter domain has a rela-
tively well-described function: it down-regulates the acti-
vated GTP-bound conformation of the small G-protein
Rac in vitro [4] and in vivo [5,6]. This function is shared
by Abr, a related protein that also contains tandem
DH-PH, C2 and GAP domains. However, Abr lacks the
N-terminal oligomerization domain.
To understand how the GAP activity of Bcr is regu-
lated, we performed a yeast two-hybrid screen with full-
length Bcr and isolated transglutaminase 2 (TG2), an
interesting multi-functional and multi-domain member
o ft h et r a n s g l u t a m i n a s ef a m i l y[ 7 ] .U n l i k eo t h e rt r a n s -
glutaminases, it is expressed in a variety of tissues and
cells and also undergoes a GTP-binding/GTPase cycle.
TG2 is located in the cytosol, in the nucleus, and on the
surface of cells [8]. It appears to have multiple functions,
including roles in differentiation, apoptosis, signal trans-
duction, adhesion and migration, wound healing, inflam-
mation and phagocytosis of apoptotic cells [8-11]. TG2
c a na d o p tac l o s e dc o n f o r m a t i o nw h e ni t sC - t e r m i n a l
domain is GTP-bound. We found that this conforma-
tion has decreased affinity for binding with Bcr.
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Bcr and is able to inhibit the Bcr GAP activity towards
Rac [7].
Transglutaminases exhibit several enzymatic activities.
These include transamidation reactions (cross-linking,
amine incorporation and acylation) as well as esterifica-
tion, deamidation and isopeptidase activities [8,12-14].
TG2 is activated in the presence of high concentrations
of calcium and converts to an open conformation. How-
ever, TG2 transglutaminase activity is latent under nor-
mal conditions because the steady-state concentration of
calcium in the cytoplasm is low. It only becomes acti-
vated under pathogenic conditions and/or extreme cel-
lular stress [15-18].
Because Bcr and TG2 can form a direct protein com-
plex, we considered the possibility that Bcr could also
act as a substrate for TG2. We here show that Bcr but
not the related Abr protein is a substrate of TG2
in vitro and in cells under conditions of cellular stress.
Interestingly, the presence of the N-terminal oligomeri-
zation domain in Bcr was responsible for this differential
modification, which may lead to its degradation under
conditions of extreme stress.
Results
TG2 cross-links Bcr
TG2 can adopt alternate conformations depending on
the presence of G-nucleotides or calcium. We previously
showed that TG2 interacts with Bcr when TG2 is in the
open, non-G-nucleotide bound conformation, which is
also the conformation adopted in the presence of cal-
cium [7]. Therefore, we investigated whether Ca
2+ could
affect the interaction between TG2 and Bcr.
As shown in Figure 1A, we pre-incubated TG2 with
Ca
2+ or with GTPgS, then added GST-BcrGAP, and per-
formed a GST pull-down assay to investigate the bind-
ing of Bcr and TG2 by immunoblotting with antibodies
to TG2. GTPgS loading of both guinea pig TG2 as well
as recombinant His-tagged TG2 reduced its binding to
BcrGAP (Figure 1A), in agreement with our previous
results [7].
The presence of calcium is known to activate TG2 and
cause auto-crosslinking [19]. Interestingly, in the pre-
sence of Ca
2+ there was increased binding of the TG2
monomer to BcrGAP and, moreover, the TG2 multimer
also was pulled down with BcrGAP (Figure 1A).
Since the transamidase activity of TG2 is Ca
2+-depen-
dent, we next assessed whether Bcr is a substrate of
TG2. We transfected COS-1 cells with Bcr, added gui-
nea pig liver TG2 to cell lysates, and performed a trans-
glutaminase assay in the presence or absence of Ca
2+.
As shown in Figure 1B, addition of exogenous TG2 pro-
duced high molecular weight Bcr aggregates in a dose-
and calcium-dependent manner. Also, we observed high
Figure 1 TG2 cross-links Bcr. A)G S T - B c r G A Pw a si n c u b a t e dw i t h
guinea pig liver TG2 (Guinea pig TG2) or His6-tagged human TG2
(Human TG2) that was loaded with GTPgS, or exposed to Ca
2+ or
treated with nothing. GST-BcrGAP was pulled down with
glutathione-agarose beads and TG2 bound to it detected by
Western blot analysis. B) Bcr-transfected COS-1 cell lysates incubated
with the indicated amounts of guinea pig TG2 with or without 5
mM CaCl2. C) HeLa cell lysates treated with CaCl2 and guinea pig
TG2 as indicated. D) COS-1 were transfected with Bcr and the
indicated TG2 constructs. Cell lysates were treated with or without
CaCl2. E) Bcr and TG2-transfected cell lysates were incubated with
EGTA and/or CaCl2 as indicated for 2 h at 37°C. Antibodies used for
Western blotting are indicated to the left. Arrows indicate guinea
pig TG2 or His6-tagged human TG2 (A) or Bcr monomer (B-E); single
asterisks indicate the top of separating gel; double asterisks indicate
the wells of the stacking gel.
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cell lysates in the presence of guinea pig TG2 (Figure
1C). To investigate if this cross-linked Bcr results from
the transglutaminase activity of TG2, TG2 wild type or
C277S (a transamidase-defective mutant) and Bcr were
co-transfected into COS-1 cells, after which a transami-
dase assay was performed. As shown in Figure 1D, the
TG2 C277S mutant did not induce aggregate formation
of Bcr, whereas expression of the wild type TG2
increased the levels of cross-linked Bcr. To confirm that
the cross-linking activity is Ca
2+-dependent, cell lysates
were also pretreated with EGTA, a chelator of Ca
2+.
Figure 1E shows that the cross-linking reaction was
blocked by 5 mM EGTA. These results indicate that
Bcr aggregate formation requires transglutaminase activ-
ity of TG2 and Ca
2+. Since Bcr naturally forms homo-
tetramers, these high molecular weight complexes will
consist of Bcr monomers but could also contain TG2,
since it was recovered in a pull-down reaction with the
Bcr GAP domain (Figure 1A), as well as other unidenti-
fied proteins.
Bcr oligomerization domain is required for cross-linking
by TG2
Bcr is a large protein containing several domains (Figure
2A). Abr (Active Bcr Related) also functions as a GAP for
R a ca n di st h eo n l yp r o t e i nt h a ts h a r e sah i g hd e g r e eo f
homology with Bcr [20]. The main difference between the
two proteins is, that Abr lacks a domain that has homol-
ogy to the N-terminal end of Bcr. This region in Bcr
includes a serine/threonine kinase domain of unknown
significance and a coiled-coil domain that allows Bcr to
form tetramers. We previously showed that the Abr GAP
domain can bind to TG2 [7]. However, as shown in Figure
2B, Abr was not detectably cross-linked by TG2.
We therefore asked if the N-terminal coiled-coil domain
of Bcr could be responsible for allowing TG2 to cross-link
Bcr. A construct that lacked the 62 N-terminal amino
acids was co-expressed with TG2 and compared to the
wild type Bcr protein. As shown in Figure 2B, whereas
Xpress-tagged Bcr wild type was cross-linked, the protein
lacking the coiled-coil region clearly was not. We con-
firmed this result by increasing the reaction time or
Figure 2 Oligomerization domain of Bcr mediates cross-linking by TG2. A) Schematic view of Bcr and Abr constructs. O, oligomerization
domain; PK, protein serine/threonine kinase domain; DH, Dbl homology domain; PH, Pleckstrin homology domain; C2, domain with homology
to C2 domains that are calcium-dependent, protein or phospholipid binding; GAP, GTPase activating protein. B) Xpress-tagged Abr, Bcr wild type
(WT), or Bcr mutant lacking the oligomerization domain (Δoligo) were co-transfected with TG2. Lysates were incubated with or without 5 mM
CaCl2. C) Lysates of cells co-transfected with TG2 and Xpress-tagged BcrWT or BcrΔoligo were incubated with CaCl2 for the indicated times.
Asterisks, as in Figure 1.
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2+:n oc r o s s - l i n k i n go ft h eB c r Δoligo
protein was detected at any length of incubation or con-
centration of calcium. In contrast, increased concentra-
tions of calcium and prolonged reaction times resulted in
progressively increased Bcr appearing in high molecular
weight complexes. After 2 hours with 5 mM CaCl2, very
little monomeric Bcr remained (Figure 2C). These results
indicate that the oligomerization domain of Bcr is cross-
linked by TG2.
Bcr is cross-linked in cells under extreme stress
In the experiments described above, calcium was added
to protein lysates. The transglutaminase activity of TG2
can also be activated in the presence of increased levels
of intracellular Ca
2+. To examine TG2-induced aggrega-
tion of Bcr in cells, COS-1 cells were transfected with
Bcr alone or together with TG2 and treated with iono-
mycin, a calcium ionophore, which induces cell death at
high concentrations [21]. As shown in Figure 3A, co-
expression of TG2 with Bcr caused a significant increase
of high molecular weight Bcr complexes in cells. Iono-
mycin treatment also caused Bcr cross-linking in cells
transfected only with Bcr, likely through activation of
endogenous TG2 (Figure 3A, lane Bcr/ionomycin).
To examine cross-linking of endogenous Bcr, we
selected primary human pulmonary artery endothelial
Figure 3 Ca
2+ influx or CoCl2 stimulates Bcr aggregation in cells. A) COS-1 cells transfected with the indicated plasmids were treated with
DMSO (Control) or 1 μM ionomycin for 1 h. Antibodies used for Western blots are indicated to the left. B) Localization of Bcr and TG2 in
HPAECs using confocal microscopy. Bar, 20 μm. C, D) HPAECs were incubated with the indicated concentrations of A23187 for 1 h (C) or CoCl2
for 24 h (D). Antibodies used for Western blotting are indicated to the left. E) Cellular localization of Bcr in HPAECs after treatment with DMSO
(Control), 20 μM A23187 for 1 h or 1000 μM CoCl2 for 24 h using confocal microscopy. DAPI was used to stain nuclei. Arrows point to some of
the intracellular Bcr aggregates. Bar, 20 μm.
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amounts of TG2 [7,22]. In addition, TG2 plays a role in
endothelial cell adhesion, proliferation and apoptosis
[23]. As shown in Figure 3B, these cells clearly
expressed Bcr protein, and Bcr co-localized with endo-
genous TG2 in the cytosol. Exposure of HPAEC to
A23187, a different calcium ionophore, induced Bcr
cross-linking, as was evident by the appearance of high
molecular weight Bcr complexes, and this was accompa-
nied by a reduction in the amount of monomers (Figure
3C). These complexes were detected as a smear of Bcr-
immunoreactive material at the top of the separation gel
and even in the wells of the stacking gel, in an A23187
dose-dependent manner.
CoCl2 is a hypoxia-mimetic agent, because like
hypoxia, it can decrease the degradation and cause subse-
quent accumulation of hypoxia-inducible factor (HIF)-
1a, a critical regulator of the cellular response to hypoxia
[24]. Also, CoCl2 induces cell death [24-28]. It was also
recently reported that hypoxia induces the expression of
TG2 via HIF-1a in some cancer cell types, but not in
others [29]. To investigate the effect of this type of
extreme stress on Bcr cross-linking by TG2, we exposed
HPAECs to increasing concentrations of this heavy
metal. As shown in Figure 3D, the treatment with high
concentrations of CoCl2 caused the appearance high
molecular weight Bcr aggregates, suggesting that hypoxic
stress can also cause covalent adducts on Bcr. CoCl2
treatment had no effect on the level of TG2 expression in
HPAECs (Figure 3D, anti-TG2 Western blot).
Treatment with A23187 or CoCl2 visibly stressed the
cells, which showed signs of apoptosis as determined by
FACS (not shown). Consistent with this, DAPI staining
showed nuclear condensation and fragmentation (Figure
3E). Interestingly, endogenous Bcr showed a prominent
punctuate staining, especially in A23187 treated cells
(Figure 3E, arrows). This is consistent with CoCl2 or
A23187 causing accumulation of Bcr aggregates in
HPAECs that are undergoing cell death.
Cross-linked Bcr is removed by proteasomal degradation
As shown in Figure 4A, pretreatment with a competitive
TG2 inhibitor, cystamine, dramatically suppressed the
appearance of Bcr high molecular weight aggregates,
further confirming that the formation of these com-
plexes is dependent on TG2 activity. Since the solubility
of some proteins changes after modification by TG2,
including monomeric forms and aggregates [30,31], we
separated cell lysates into TritonX-100 soluble and inso-
luble fractions. As shown in Figure 4B, the high molecu-
lar weight Bcr aggregates were mainly present in the
TritonX-100-insoluble fraction, and more Bcr mono-
mers were present in the TritonX-100-soluble fraction.
It has been shown that TG2 promotes the proteasomal
degradation of some proteins including nucleophosmin
and PTEN [31,32]. To investigate if the high molecular
weight Bcr aggregates are degraded in a proteasome-
dependent pathway, HPAECs were pretreated with
MG132, a proteasomal inhibitor, before exposure to the
calcium ionophore. Interestingly, pretreatment with
MG132 caused accumulation of the high molecular weight
aggregates of Bcr (Figure 4C). These results suggest that
Bcr aggregates, resulting from cross-linking by TG2, are
ultimately disposed of by proteasomal degradation.
Figure 4 Bcr aggregates are degraded by a proteasome-
dependent pathway. A) HPAECs were pretreated with 100 μM
cystamine for 30 min, then incubated with 20 μM A23187 for 1 h.
Cell lysates were subjected to Western blot analysis with the
antibodies indicated to the left. B) After incubation with A23187 for
1 h, HPAECs were lysed and separated into Triton X-100 soluble (TX-
soluble) or insoluble (TX-insoluble) fractions. The same amount of
protein was subjected to Western blot for Bcr, TG2, or b-actin. C)
HPAECs were pretreated with a proteasome inhibitor, MG132 (50
μM for 30 min), followed by incubation with the indicated
concentrations of A23187. Antibodies used for Western blotting of
lysates are indicated to the left. Asterisks, as in Figure 1.
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Binding of guanine nucleotides or of Ca
2+ to TG2 is
known to inversely regulate its conformation and its
transglutaminase activity: whereas Ca
2+-bound TG2 has
an open conformation and is active as a transglutami-
nase, TG2 bound to G-nucleotides is enzymatically inac-
tive, with a closed conformation [8,16,33]. Although Bcr
binds preferentially to the open conformation of TG2,
the interaction is not dependent upon TG2 being active
as a transglutaminase because the interaction also
occurred with the catalytically inactive TG2 C277S
mutant [7]. Our current results demonstrate that Bcr
also binds quite strongly to the activated, calcium-
bound form of TG2. Together, these results suggest that
under normal physiological conditions, TG2 interacts
with Bcr even though the calcium concentration is not
sufficient for activation of the transglutaminase activity.
Under conditions of cellular stress caused by high cal-
cium influx, the calcium-bound, enzymatically active
form of TG2 then uses Bcr as a substrate for cross-
linking.
Apart from high calcium concentrations, other cellular
stressors that have been reported to involve TG2 activa-
tion include exposure to bacterial endotoxin and gluta-
mate-mediated excitotoxic damage of neuronal cells
[34]. However, we did not detect Bcr aggregates in pri-
mary rat neurons exposed to glutamate or bone mar-
row-derived macrophages treated with LPS (not shown).
Also, Bcr aggregates were only detected in HPAECs
stressed by CoCl2 or A23187 treatment and not by
other stimulants including LPS, TNF-a, and thrombin
(data not shown). Therefore the formation of Bcr aggre-
gates may be specific only for certain types of cell stress
that lead to cell death.
To the best of our knowledge, the biological effect of
TG2 cross-linking due to calcium overload has not been
conclusively defined for any protein. However, based on
what is known about Bcr structure and function, we can
envision three possible consequences of Bcr cross-
linking under conditions of calcium influx and apopto-
sis. One is a role that was postulated in general for the
consequences of TG2 cross-linking activity under condi-
tions of cell death: TG2 activity could produce a pro-
tein-rich “shell” that would prevent leakage of cellular
components to the extracellular space and, through this,
reduce inflammation that would otherwise be provoked
by cell debris [35-37]. Bcr contains a C2 domain that, in
other proteins, is a calcium-binding module. The adja-
cent PH domain was recently shown to be able to bind
to keratin 10, b-tubulin and collagen IV [38]. Because
the high molecular weight Bcr aggregates found in our
study were mainly present in the TritonX-100-insoluble
fraction, one could speculate that Bcr, due to multiple
cellular interactions including its own capacity to form
homo-tetramers, acts as a calcium-induced scaffold for
the formation of high molecular weight aggregates
including elements of the cytoskeleton. This function
would be consistent with the overall activity of Bcr to
negatively regulate inflammation in vivo [6,7].
A second speculative role is in the area of vesicle
transport. The PH domain of Bcr was shown to bind to
specific mono-phospholipids PtdIns(3)P and PtdIns(4)P
that are present in early endosomal membranes and in
the Golgi, respectively [38]. Moreover, Bcr binds to the
endosomal sorting protein TSG101 [39], which is also
present in exosomes [40]. Since cross-linking of Bcr
could affect its GAP activity on Rac, this in turn could
potentially affect the trafficking of extracellular TG2.
Finally, our results suggest that cross-linked Bcr is tar-
geted for degradation. Since Bcr is a negative regulator
of Rac, its removal would lead to increased levels of
activated Rac, which has been associated with both
decreased and increased apoptosis, depending on the
cell type.
Bcr contains a unique N-terminal coiled-coil domain
that has been a focus of significant interest because it is
responsible for deregulation of the tyrosine kinase activ-
ity of Abl within the Bcr/Abl fusion protein that causes
the development of some types of leukemia. Interest-
ingly, this domain also allows the formation of Bcr
homodimers and tetramers [2,3,41,42]. We here found
that it plays an important role in the formation of Bcr
aggregates. The domain encompasses residues 2-63,
which includes two lysine and five glutamine residues
that could be involved in the cross-linking reaction, but
the exact requirements for cross-linking remain to be
determined. It will also be of interest to address if TG2
is able to cross-link the N-terminal oligomerization
domain of the Bcr/Abl oncoprotein.
Conclusions
We recently showed that TG2 directly interacts with Bcr
and regulates the GAP activity of Bcr under normal
physiological conditions. Here, we present data showing
that Bcr is a substrate for TG2 transglutaminase activity
in vitro and in cells. Under extreme stress, TG2 cross-
links Bcr into high molecular weight complexes which
are removed by a proteasomal degradation pathway.
These results suggest that Bcr is regulated by TG2 via
different mechanisms, depending on the physiological
conditions in the cell.
Methods
Plasmids and Antibodies
Full length human TG2 wild type, TG2 C277S cDNAs
and Xpress-tagged Bcr wild type have been described
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isolated the N-terminal end of Bcr with deletion of
amino acid residues 2-63 from a previously described
474 bp subclone by digestion with Eag I × Xho I [43].
The 3.5 kb 3’ end of BCR was isolated from a cDNA
clone in pSK (B1/SK) by digestion with Xho I × Xba I.
These two fragments were combined in pcDNA3.1/HisB
digested with Not I × Xba I. Xpress-tagged Abr was
constructed in a 3-way ligation between a 5’ 0.45 kb
BamHI-BstEII, a 3’ 2.2 kb BstEII-EcoRI fragment and
vector pcDNA/HisC digested with BamHI × EcoRI. The
amino-terminal Abr end is the one expressed on the
non-neuronal isoform. Bcr (N-20), Xpress and TG2
antibodies were from Santa Cruz Biotechnology (Santa
C r u z ,C A ) ,I n v i t r o g e n( C a r l s b a d ,C A )a n dL a bV i s i o n
(Fremont, CA), respectively. MG132 and monoclonal
Bcr (Ab-2) antibodies were from EMD Chemicals
(Gibbstown, NJ).
Cell culture
COS-1 and HeLa cells were obtained from the Ameri-
can Type Culture Collection (Manassas, VA). Human
p u l m o n a r ya r t e r ye n d o t h e l i a lc e l l s( H P A E C s )w e r ef r o m
Invitrogen, and were cultured in Medium 200 with low
serum growth supplement according to the manufac-
turer’s protocol. They were used at passage 4-6.
GST pull-down assay
Recombinant GST-BcrGAP and His6-tagged human
TG2 were purified from E. coli as described [4,44]. For
GTPgSo rC a
2+ loading of TG2 and in vitro binding
assays, 12.5 pmol of guinea pig TG2 (Sigma, St. Louise,
MO) or His6-tagged TG2 was incubated in 25 mM Tris,
pH 7.4, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 2 mM
MgCl2,1 0 0m MN a C l ,0 . 1 %I g e p a l ,1m Mp h e n y l -
methylsulfonyl fluoride (PMSF), 10 μg/ml aprotinin,
10 μg/ml leupeptin, 10% glycerol, and 100 μMG T P gS
or 5 mM CaCl2 for 20 min at 30°C. 12.5 pmol of GST-
BcrGAP was added and allowed to form a complex for
1 h at 4°C, followed by incubation with glutathione-
agarose beads for 1 h at 4°C.
Transfection and cross-linking assay
COS-1 cells were transfected with Plus reagent and
Lipofectamine (Invitrogen) according to the manufac-
turer’si n s t r u c t i o n sa n dg r o w nf o r2d a y sp r i o rt ot h e
assay. For cross-linking assays, cells were lysed in trans-
glutaminase assay buffer (50 mM Tris, pH 8.0, 150 mM
N a C l ,1 %T r i t o nX - 1 0 0 ,1m MD T T ,1m MP M S F ,
10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 μg/ml pepsta-
tin). Cell lysates (50 μg) were incubated with or without
5m MC a C l 2 for 2 h at 37°C, based on previously
reported concentrations of 5 mM or more of CaCl2
added to in vitro assays, using cell extracts or purified
proteins [29,45]. In some experiments, guinea pig TG2
or EGTA was added to the reactions.
Treatment with calcium ionophores or CoCl2
Transfected COS-1 cells were treated with 1 μMi o n o -
mycin for 1 h. HPAECs were treated with 10-40 μM
A23187 for 1 h or with CoCl2 for 24 h and lysed with
SDS lysis buffer (50 mM Tris, pH 6.8, 2% SDS, 10% gly-
cerol). For some experiments, cells were pretreated with
cystamine or MG132 for 30 min. For separation of Tri-
tonX-100-soluble and insoluble fractions, cells were
lysed in 50 mM Tris, pH 7.6, 150 mM NaCl, 1% Triton
X - 1 0 0 ,5m ME D T A ,1m MP M S F ,1 0μg/ml aprotinin,
10 μg/ml leupeptin, 1 μg/ml pepstatin and centrifuged
at 16000 g for 15 min. The supernatants were collected
as TritonX-100-soluble fractions and insoluble pellets
were solubilized in SDS lysis buffer as TritonX-100 inso-
luble fractions.
Immunofluorescence
HPAECs were grown on fibronectin-coated coverslips
(Fisher Scientific) for 1-2 days and then treated with
A23187 or CoCl2. Cells were washed twice with PBS
and fixed in 4% paraformaldehyde (Electronic Scientific
Co., Hatfield, PA) (15 min at room temperature [RT]),
followed by permeabilization in 0.2% Triton X-100
(15 min, RT). Cells were blocked in 1% bovine serum
albumin in PBS and stained with TG2 antibodies (Lab
vision Ab-4, 5 μg/ml) and Bcr antibodies (EMD chemi-
cals Ab-2, 1 μg/ml) in blocking solution overnight at
4°C, followed by incubation with Cy3-conjugated anti-
mouse IgG and FITC-conjugated anti-rabbit IgG antibo-
dies (Jackson ImmunoResearch Laboratories, Inc, West
Grove, PA). After mounting in Vectashield containing
4’,6’-diamidino-2-phenylindole (DAPI; Vector Labora-
tories, Burlingame, CA), cell images were acquired with
a Zeiss 710 confocal microscope.
Abbreviations
Bcr: breakpoint cluster region; TG2: transglutaminase 2; GAP: GTPase
activating protein; HPAECs: human pulmonary artery endothelial cells; PMSF:
phenylmethylsulfonyl fluoride; RT: room temperature; DAPI: 4’,6’-diamidino-2-
phenylindole; DMSO: dimethyl sulfoxide.
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